Logo image of PALI

PALISADE BIO INC (PALI) Stock Fundamental Analysis

NASDAQ:PALI - Nasdaq - US6963894026 - Common Stock - Currency: USD

1.05  +0.04 (+3.96%)

Fundamental Rating

2

Taking everything into account, PALI scores 2 out of 10 in our fundamental rating. PALI was compared to 551 industry peers in the Biotechnology industry. While PALI seems to be doing ok healthwise, there are quite some concerns on its profitability. PALI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PALI had negative earnings in the past year.
In the past year PALI has reported a negative cash flow from operations.
In the past 5 years PALI always reported negative net income.
In the past 5 years PALI always reported negative operating cash flow.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of PALI (-132.70%) is worse than 82.94% of its industry peers.
Looking at the Return On Equity, with a value of -192.71%, PALI is doing worse than 66.79% of the companies in the same industry.
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROIC N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

PALI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

5

2. Health

2.1 Basic Checks

PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
PALI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PALI has been increased compared to 5 years ago.
Compared to 1 year ago, PALI has an improved debt to assets ratio.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

PALI has an Altman-Z score of -20.34. This is a bad value and indicates that PALI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -20.34, PALI is not doing good in the industry: 84.75% of the companies in the same industry are doing better.
PALI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.34
ROIC/WACCN/A
WACC10.81%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

PALI has a Current Ratio of 3.24. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PALI (3.24) is worse than 62.61% of its industry peers.
PALI has a Quick Ratio of 3.24. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
PALI's Quick ratio of 3.24 is on the low side compared to the rest of the industry. PALI is outperformed by 60.62% of its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

PALI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.08%, which is quite impressive.
PALI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.81% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.38%
EPS Next 2Y38.45%
EPS Next 3Y24.23%
EPS Next 5Y13.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2030 2031 2032 50M 100M 150M 200M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PALI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PALI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as PALI's earnings are expected to grow with 24.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.45%
EPS Next 3Y24.23%

More info and screens

0

5. Dividend

5.1 Amount

PALI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALISADE BIO INC

NASDAQ:PALI (8/4/2025, 1:37:11 PM)

1.05

+0.04 (+3.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11
Inst Owners5.53%
Inst Owner Change0%
Ins Owners0.46%
Ins Owner Change0%
Market Cap5.04M
Analysts84.44
Price Target10.88 (936.19%)
Short Float %17.06%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)23.66%
Max EPS beat(2)32.15%
EPS beat(4)3
Avg EPS beat(4)12.73%
Min EPS beat(4)-11.13%
Max EPS beat(4)32.15%
EPS beat(8)4
Avg EPS beat(8)3.92%
EPS beat(12)8
Avg EPS beat(12)37.63%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)19.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-7.66
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS1.56
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z -20.34
F-Score2
WACC10.81%
ROIC/WACCN/A
Cap/Depr(3y)144.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.76%
EPS Next Y87.38%
EPS Next 2Y38.45%
EPS Next 3Y24.23%
EPS Next 5Y13.81%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.52%
OCF growth 3YN/A
OCF growth 5YN/A